Syncom Formulations (India) Ltd (BSE: 524470) is an Indore, Madhya Pradesh-based company in the Pharmaceuticals industry. With a market capitalisation of ₹1,904 Cr, it ranks #1,270 by market cap among the 6,197 Indian listed companies on FinBizNet, and #21 of 63 in Pharmaceuticals. At ₹20.33 (as of 16 Nov 2026), the share price is 26.0% below its 52-week high of ₹27.49 and 99.1% above its 52-week low of ₹10.21. The share price is up 26.3% over one year and up 33.1% over three months.
| Current Price | ₹20.33 |
|---|---|
| Market Cap | ₹1,904 Cr |
| BSE Code | 524470 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 25 |
| Return on Equity | 20.19% |
| Return on Assets | 9.33% |
| 52-Week Range | ₹10.21 – ₹27.49 |
| 1-Year Price Change | +26.3% |
| 3-Month Price Change | +33.1% |
| Beta (1Y) | 0.91 |
| Dividend Yield | 0.49% |
| Headquarters | Indore, Madhya Pradesh |
| Website | www.syncomformulations.com |
| Revenue | ₹142 Cr |
|---|---|
| Net Profit | ₹27 Cr |
| Net Margin | 18.7% |
| EPS (Basic) | ₹0.28 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Syncom Formulations (India) Ltd reported revenue of ₹142 Cr in Q2 FY27, up 16.8% from ₹122 Cr in Q2 FY26 and up 13.2% from ₹126 Cr in Q1 FY27. It posted a net profit of ₹27 Cr for the quarter, against a net profit of ₹17 Cr in Q2 FY26 (up 60.5%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹115 Cr (Q3 FY26) to ₹149 Cr (Q4 FY25). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹142 Cr | ₹27 Cr | 18.7% |
| Q1 FY27 | ₹126 Cr | ₹25 Cr | 19.8% |
| Q4 FY26 | ₹135 Cr | ₹25 Cr | 18.6% |
| Q3 FY26 | ₹115 Cr | ₹19 Cr | 16.4% |
| Q2 FY26 | ₹122 Cr | ₹17 Cr | 13.6% |
| Q1 FY26 | ₹117 Cr | ₹16 Cr | 13.5% |
| Q4 FY25 | ₹149 Cr | ₹18 Cr | 11.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 50.57% of Syncom Formulations (India) Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 33.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
1. Pharmaceuticals Drugs & Formulations-This segment engages in manufacturing, selling, and dealing in pharmaceuticals and formulations. 2. Trading of Commodities-This segment engages in trading of commodities. 3. Renting of Property-This segment engages in the rental of properties. 4. Segment Adjustment-0
1. Pharmaceuticals Drugs & Formulations-99.1% 2. Trading of Commodities-0.2% 3. Renting of Property-0.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Syncom Formulations (India) Ltd | ₹1,904 Cr | 25 | 20.19% | ₹142 Cr | +26.3% |
Listed by market capitalisation. Ratios are shown for context only.
Syncom Formulations (India) Ltd is trading at ₹20.33, with a market capitalisation of ₹1,904 Cr.
Syncom Formulations (India) Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Syncom Formulations (India) Ltd has a P/E of 25 and a return on equity of 20.19%.
Syncom Formulations (India) Ltd is listed on the BSE under the scrip code 524470.
Syncom Formulations (India) Ltd's share price is up 26.3% over one year and up 33.1% over three months. Its 52-week range is ₹10.21 to ₹27.49.
In Q2 FY27, Syncom Formulations (India) Ltd reported revenue of ₹142 Cr and net profit of ₹27 Cr, with basic EPS of ₹0.28 (consolidated, parsed from the company's exchange filing).
Syncom Formulations (India) Ltd reported revenue of ₹142 Cr in Q2 FY27, up 16.8% from ₹122 Cr in Q2 FY26 and up 13.2% from ₹126 Cr in Q1 FY27.
Promoters held 50.57% of Syncom Formulations (India) Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.